AIM ImmunoTech Inc.
AIM
Jodie situation report
AIM ImmunoTech Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
- AIM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AIM's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind AIM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AZNAstraZeneca PLCpartnerMay 15, 2026 ▾
“AIM strongly believes that such a Phase 3 study will be possible following the ongoing Phase 2 clinical study evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic panc…”
MRKMerck & Company, Inc.partnerNov 17, 2025 ▾
“We believe that data from the study, which is being conducted by the University of Pittsburgh Medical Center and funded by a Merck grant, demonstrated that when combining three drugs – Ampligen and pembrolizumab, which are both immune therapies, with cisplati…”
MRKMerck & Company, Inc.competitorMar 27, 2026 ▾
“The study was temporarily suspended due to the Merck discontinuation of Intron-A production.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AIM is currently a Leader in the organic co-movement group Immuno-Oncology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AIM; it is not active in the latest market snapshot.